Novartis Cosentyx Gets European Expanded Approvals For Use In Childhood Arthritic Conditions

Novartis Cosentyx Gets European Expanded Approvals For Use In Childhood Arthritic Conditions

By, Admin 28 June 2022

Novartis Announced The European Commission (Ec) Has Approved Cosentyx (Secukinumab), Used Alone Or In Combination With Methotrexate, In The Juvenile Idiopathic Arthritis (Jia) Categories Of Enthesitis-Related Arthritis (Era) And Juvenile Psoriatic Arthritis (Jpsa) In Patients 6 Years And Older Whose Disease Has Responded Inadequately To, Or Who Cannot Tolerate, Conventional Therapy.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!